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The identification of well-defined phenotypes along
the course of the disease may open new avenues for
personalized management in osteoarthritis (OA). In
vivo research carried out in various animal models as
well as epidemiological and clinical data support the
existence of a particular phenotype – osteoporotic
OA. In fact, subchondral bone has become a potential
therapeutic target in OA. Depending on the ratio
between formation and resorption, subchondral bone
remodeling can culminate in either a sclerotic or an
osteoporotic phenotype. Patients with osteoporotic
OA may thus achieve clinical and structural benefit
from treatment with bone-targeted interventions.porotic OA phenotypes may enable individualized targeted
therapy [3].Subchondral bone has become a potential therapeutic tar-
get in osteoarthritis (OA). In a previous issue of Arthritis
Research & Therapy, Wang and colleagues demonstrate
that osteoporosis aggravates cartilage damage in an experi-
mental model of knee OA in rats [1]. Interestingly, the au-
thors also describe that extracorporeal shockwave therapy
(ESWT), a mechanical therapeutic intervention prob-
ably acting at subchondral bone, may reduce OA progres-
sion [1]. The significance of these findings in experimental
osteoporotic OA relates to the search for well-defined
phenotypes in human OA that will lead to personalized
therapy.
The controversy regarding the relationship between
subchondral bone quality and cartilage integrity origi-
nates from the complex biological and mechanical na-
ture of the osteochondral junction [2]. OA progression
is often accompanied by increased subchondral bone re-
modeling that enables mechanical forces to dynamically* Correspondence: gherrero@fjd.es
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icle, unless otherwise stated.modify its structure. Depending on the ratio between
formation and resorption, subchondral bone can exhibit
either a sclerotic or an osteoporotic phenotype [3].
These phenotypes may represent up to 70% and 30% of pa-
tients in daily practice, respectively [4]. Furthermore, OA
in females can display a different pathogenic profile from
OA in males. In this sense, it is reasonable to underline the
consequences of estrogen deficiency during menopause
[5]. A low estrogen state could induce a deleterious effect
on all articular tissues of the knee joint, the subchondral
bone being particularly affected due to its capacity for high
bone turnover. Thus, during early post menopause, estro-
gen deficiency may be a risk factor for the development of
knee OA. Taking all these facts into consideration, the
characterization of patients with either sclerotic or osteo-
The effects of estrogen deficiency on the knee joint have
been reported in various experimental animal models of
OA. The findings obtained by Wang and colleagues on
subchondral bone quality and articular cartilage damage
support previous research carried out in rabbits, in which
osteoporosis aggravated instability-induced OA [6]. In this
combined model, the induction of systemic and subchon-
dral osteoporosis associated with increased bone remodel-
ing resulted in worse cartilage damage compared with
control animals. Greater fragility of the subchondral bone
was suggested to account for the aggravation of cartilage
damage when early OA and osteoporosis coexist [7]. In a
further study carried out in the same model, the intermit-
tent administration of parathyroid hormone 1-34, a bone-
forming agent, was used to increase subchondral bone
density and quality [8]. As a consequence, the improve-
ment of subchondral bone integrity was associated with
reduced progression of cartilage damage in OA preceded
by osteoporosis. In a similar approach, the inhibition of
bone resorption by pamidronate in osteoporotic mice alle-
viated the instability-induced OA histological score with a
reduction in the expression of aggrecanases [9]. Severalensee BioMed Central Ltd. This is an Open Access article distributed under the
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osteoporosis induces an accelerated progression of knee
OA that can be reversed not only by bone-forming agents
but also by antiresorptive drugs.
These findings in animal models could be translated
to humans, and together with epidemiological and clin-
ical data they support the existence of a particular
phenotype – osteoporotic OA [10]. Indeed, this pheno-
type characterized by decreased density and high re-
modeling at subchondral bone defines a subgroup of
patients treatable with specific agents. In fact, beneficial
effects of bone-acting drugs in OA are increasingly re-
ported, but reliable conclusions regarding their efficacy
are hindered by methodological drawbacks in study de-
sign [10]. Identifying patients with osteoporotic OA
may improve the success of bone-directed agents.
The original approach of using ESWT in OA by Wang
and colleagues remains intriguing. These authors have
reported previously that the application of ESWT to
subchondral bone of the proximal tibia showed a chon-
droprotective effect in the initiation of knee OA and re-
gression of established OA of the knee in rats. These
effects were attributed to the ESWT multifunctional ac-
tions on cartilage and bone. Yet achieving such benefi-
cial effects in this osteoporotic OA model suggests that
the main mechanism of action of ESWT may be improv-
ing subchondral bone structure [1]. However, some limi-
tations on the study design and the lack of adequate
standardization of dosages and optimal frequency, as
well as little information regarding the molecular mecha-
nisms underlying the effects of ESWT, hold back the
achievement of solid results. In any case, this study points
out the potential benefit of nonpharmacological interven-
tions aiming to improve mechanical properties of articular
tissues in OA.
In summary, the study by Wang and colleagues further
supports the existence of the osteoporotic OA subtype
and the potential benefit of bone-acting therapeutic in-
terventions. Consequently, the identification of patient
phenotypes along with the discovery of specific thera-
peutic interventions targeting relevant pathogenic mech-
anisms during the course of the disease could lead to a
personalized approach to the management of OA.
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